Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in the Beginning | Once Safety Profile is Cleared, Open Enrollment Occurs
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in the Beginning | Once Safety Profile is Cleared, Open Enrollment Occurs